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The peroxisome proliferator, WY 14,643 exhibits a pure non-competitive inhibition pattern in the
aldehyde reduction and in alcohol oxidation activities of human Aldose reductase (hAR). Fluorescence
emission measurements of the equilibrium dissociation constants, Kd, of oxidized (hAR•NADP+)
and reduced (hAR•NADPH) holoenzyme complexes display a 2-fold difference between them. Kd
values for the dissociation of WY 14,643 from the oxidized (hAR•NADP+•WY 14,643) and reduced
(hAR•NADPH•WY 14,643) ternary complexes are comparable to each other. The ternary complex
structure of hAR•NADP+•WY 14,643 reveals the first structural evidence of a fibrate class drug binding
to hAR. These observations demonstrate how fibrate molecules such as WY 14,643, besides being
valued as agonists for PPAR, also inhibit hAR.
Hyperlipidemia is a medical condition involving elevated levels of lipids in the blood, such as cholesterol and
triglycerides. It causes blood vessels occlusion and increases the risk of developing atherosclerosis, coronary heart
disease, strokes, hypertension or diabetes. According to March 2015 CDC report over 73.5 million adults (31.7%)
in the United States have high low density lipoprotein, or “bad,” cholesterol. Clofibrate amphipathic carboxylic
acids of a class known as fibrates, or peroxisome proliferators, are drugs once widely used in the clinical management of hyperlipidemia1. However, use was discontinued in the year 2002 due to its adverse effects of myopathy,
myositis and rhabdomyolysis leading to acute renal failure. Pleiotropic response to fibrates, is characterized in the
short term by upregulation of peroxisomal fatty acid P-oxidation enzymes and cytochrome P450 IVA in liver, peroxisomal proliferation, increased cell division and liver weight gain and in the longer term, pre-neoplastic lesions
and eventually carcinomas of the liver. Clofibric acid glucuronide has been shown to mediate the formation of
covalently bound clofibric acid-albumin adducts in vitro2 and clofibric acid-plasma protein adducts are identified
in man and rat3. The covalent binding of drugs to tissue macromolecules has traditionally been associated with
toxicity4–7.
Interestingly, a synthetic derivative of clofibrate, [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic
Acid (WY 14,643) (Fig. 1), is a potent anti hypercholesterolemic agent8. It is currently under investigation for
prevention of heart failure resulting from hyperlipidemia. WY 14,643 has been shown to produce an 18-fold
increased capacity in oxidization of palmitoyl-coenzyme A in rat livers9 and exert cardioprotection in a rat model
of ischemia-reperfusion injury10. Also, WY 14,643 has been shown to improve metabolic indices, steatosis and
ballooning in diabetic mice with non-alcoholic steatohepatitis11. A major mediator of WY 14,643 action is the
ligand-activated transcription factor, peroxisome proliferator-activated receptor alpha (PPARα)12. Overall WY
14,643 is considered a potent murine (PPAR)α agonist and a weak PPARγ agonist13. Through this agonistic
behavior, WY 14,643 increases PPAR transcriptional activity, thereby increasing levels of fatty acid oxidation, cell
division, and cancer.
WY 14,643 has been known as a specific PPARαagonist since 1990. Only more recently, in 2006, this same
inhibitor was also discovered to target Aldose reductase (hAR)14,15 and AKR1B1016, the Aldo-keto reductase protein family members. Inhibition kinetic data for WY 14,643 are Kii (intercept inhibition constant) =  Kis (the slope
inhibition constant) =  1.8 μM and 1.67 μM and 1.63 μM for hAR catalyzed forward reaction and reverse reaction, respectively15. This finding suggested WY 14,643 follows a classical non-competitive pattern of inhibition
with respect to the reduction of DL-glyceraldehyde and pure non-competitive mode in the oxidation of benzyl
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Figure 1. Chemical Structure of 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid, WY 14,643,
Pirinixic acid.
alcohol15. However molecular interactions, their corresponding binding affinity, stoichiometry, or location associated with hAR and WY 14,643 were yet to be revealed. AR catalyzed reduction of glucose to sorbitol is the first
step of the polyol pathway through which less than 3% of the glucose flow in healthy human cells. However, under
hyperglycemic or pre-diabetes conditions AR is overexpressed and the activity of this enzyme is implicated in
the pathogenesis of most of the diabetic complications17–21. The sorbitol that is formed is not readily metabolized
and leads to accumulation within the cell22,23. In addition, AR has also been linked in increased cardiovascular
mortality rate with diabetic autonomic neuropathy patients24. These observations form the foundation to develop
specific effective AR inhibitors.
We have determined the crystal structures of WY 14,643 and the hAR•NADP+•WY 14,643 ternary complex.
Also we have applied fluorescence quenching methodologies to determine equilibrium dissociation constants
binding of NADPH and NADP+ individually to apo hAR and binding of WY 14,643 to hAR•NADPH and hAR•
NADP+ binary complexes separately. Here we report 1) these binding results, 2) protein free structure of WY
14,643, 3) hAR•NADP+•WY 14,643 ternary complex structure and describe conformational changes due to WY
14,643 binding to the hAR•NADP+ binary complex.

Results

Fluorescence phenomenon seen by cofactor and inhibitor binding to hAR may be affected partly by charge
transfer processes between groups/atoms. The characteristics of fluorescence reflect the outcome of the binding
strength between the ligand and the protein that corresponds to the microenvironment and the conformational
changes associated with hAR and other components.

Fluorescence effect induced by cofactor and WY 14,643 binding. The fluorescence intensities of
hAR decreased gradually when the concentrations of quenchers (i.e. inhibitor and cofactors) were increased. The
observed fluorescence data were used for calculating the fluorescence quenching (Q% =  (F0 −  F)/F0) where F is
the measured fluorescence and F0 is the fluorescence in the absence of quenchers.
The fractional change in fluorescence increased parabolically as the concentration of NADPH, NADP+
rose. The correlation between the average of triplicate measurements and simulated trend is shown in Fig. 2a,b
(Table 1) for binding of NADPH to hAR and NADP+ to hAR, respectively. Our fluorescence emission measurements indicate that the equilibrium dissociation constants, Kds, are 0.210 μM and 0.48 μM for NADP+ and
NADPH, respectively. Similar fractional changes in fluorescence followed a saturation pattern with increasing
concentration of WY 14,643 in the presence of 60 μM NAPDH and NADP+ (Fig. 2c,d; Table 1). Furthermore the
Kd values are very similar for WY 14,643 binding with hAR•NADP+ (0.104 μM) and hAR•NADPH (0.110 μM)
binary complexes.
Structure of hAR•NADP+•WY 14,643 Complex. The ternary complex structure, hAR•NADP+•WY
14,643, contains two protein molecules in the asymmetric unit (molA and molB). The two protein molecules are
related by a non-crystallographic two-fold rotation axis. They superimpose with an RMS deviation of 0.07 Å over
316 pairs of Cαatoms. The ternary complex structure was refined to 1.65 Å resolution with the final R factor of
16.8%, and Rfree of 19.5%. The structure contains a total of 632 protein residues corresponding to 316 amino acids
for each protein molecule, two cofactors NADP+, two WY 14,643 molecules, 8 sulfate ions, and 569 water sites.
The mean B values for the protein, cofactor, WY 14,643, sulfate and water atoms are 23.0, 14.6, 27.5, 49.6, and
33.9 Å2, respectively. Further crystallographic parameters are listed in Table 2.
Atomic Interactions in hAR•NADP+•WY 14,643 Complex.

Polar and vdW interactions stabilize an
extended conformation of the cofactor. The detailed polar interactions between the cofactor and the protein
atoms are shown in Table 3. One NADP+ molecule binds each molecule of the dimer of hAR in the ternary complex and the two cofactors in the asymmetric unit have an RMS deviation of 0.05 Å over 48 pairs of atoms.
WY 14,643 binds hAR at the C-terminal opening of the α/βbarrel, near the cofactor binding site (Fig. 3a). In
our characterization of inhibitor binding, we divide the inhibitor into three regions, the carboxylate moiety, the
pyrimidine moiety, and the 2,3-xylidino moiety. The carboxylate moiety of WY 14,643 anchors the inhibitor to
hAR through three hydrogen bonds (Table 4) with Tyr48(OH), His110(NE2) and Trp111(NE1). It also makes a
Scientific Reports | 6:34394 | DOI: 10.1038/srep34394
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Figure 2. Fluorescence measurements for the determination of binding dissociation constant corresponding to (a).
NADPH titration curve for hAR•NADPH complex formation (b). NADP+ titration curve for hAR•NADP+
complex formation (c). WY 14,643 titration curve for WY 14,643•hAR•NADPH complex formation and (d).
WY 14,643 titration curve for WY 14,643•hAR•NADP+ complex formation, respectively.

Complex
Quencher (L)
NADP+

Kd(E-NADP+) (μM)

Kd(E-NADPH) (μM)

0.210 ±  0.01;
n =  1.05 ±  0.03
0.48 ±  0.04;
n =  1.25 ±  0.1

NADPH
Complex

WY 14,643

hAR•NADP+

hAR•NADPH

104.6 ±  4.2;
n =  1.37 ±  0.05

110 ±  5.0;
n =  1.25 ±  0.06

Table 1. Equilibrium dissociation constants (Kd) and stoichiometry coefficients (n) of NADP+ and
NADPH binding with hAR and those of WY 14,643 binding with hAR•NADP+/NADPH complexes.

vdW contact with the nicotinamide ring, atom C3N (Fig. 3a; Table 4). Proximal to the carboxylate, the pyrimidine
moiety of the inhibitor makes vdW contacts with the aromatic rings of Trp20, Trp219, and Phe122. Furthest from
the carboxylate, the 2,3-xylidino moiety makes limited vdW contact with only one residue, Phe122. The density
for this moiety is correspondingly weaker compared to the pyrimidine and carboxylate moieties. This evidence
suggests that the two torsion angles between the pyrimidine and xylidino rings are free to rotate (i.e. rotate around
the single bonds C4-NAM and NAM-CAT, nomenclature defined in Fig. 3b). We observe one molecule of WY
14,643 bound to each of the two hAR molecules. The RMS deviation between the two WY 14,643 molecules is
0.05 Å over 21 pairs of inhibitor atoms. Broken residual density at the 3.5 σlevel suggests there may be an additional, lower occupancy, mode of binding of WY 14,643 in this same pocket.
The conformation of the cofactor in the binary and ternary hAR complexes that is found in the dimeric crystal form is very similar. The RMS deviation is 0.25 Å between the dimer of hAR in the holoenzyme (PDB ID
3Q65) and the dimer of WY 14,643-bound ternary complex (624 pairs of Cαatoms). Notably, in the ternary hAR
complex, the loop from residue 114 to 137 shifts closer to the 2,3-xylidino moiety of the inhibitor (Fig. 4a,b) in
both molA and molB compared to the binary complex crystallized in the same space group. The RMS deviation
corresponding to this loop (258 to 258 atoms) alone is 0.47 Å between the binary and ternary hAR complexes.
The WY 14,643 inhibitor itself undergoes striking conformational changes upon binding to hAR. Comparison
of WY 14,643 conformations in the protein free (Fig. 3b; Table 5) and hAR ternary complex structure reveals large
Scientific Reports | 6:34394 | DOI: 10.1038/srep34394
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Structures

hAR•NADP+•WY 14,643

Data collection, processing and structure refinement
Wavelength (Å)

0.9795

Space group

P212121

Unit cell parameters
a, b, c (Å)

83.3, 85.9, 104.4

α, β, γ (°)

α  =  β  =  γ  =  90

Diffraction data
Resolution range (Å)
Unique reflections

100–1.65 (1.74–1.65)
90,282 (12,715)

Rmerge (%)

5.8 (45.2)

Completeness (%)

99.5 (97.2)

Redundancy

5.7 (3.9)

I/σ (I)

14.8 (2.5)

Refinement
Resolution range used in refinement (Å)
Reflections used in refinement (work/free)
Final R values (work/free) (%)
Protein atoms

66–1.65 (1.69–1.65)
85,620 (4,556)
16.8 (31.5)/19.5 (29.9)
5,099

Cofactor atoms

96

Water molecules

569

Sulfate atoms

40

rmsd values
Bonds (Å)
Angles (°)
PDB ID code

0.014
1.7
5HA7

Table 2. Crystallographic Statistics of the hAR•NADP+•WY 14,643 complex structure.
deviations in two torsion angles (Fig. 5a,b). The first deviation is near the carboxylate moiety, involving ~180°
rotation around the SAN-CAJ bond. This rotation is required to accommodate the hydrogen bonding geometry
of the carboxylate with Tyr 48, His110, and Trp111 side chains and simultaneously avoid the clash between the
pyridinium ring Cl atom and the side chain of Val47. The second deviation involves a ~180° rotation between the
two aromatic rings, around the CAT-NAM bond. The rotation avoids collision between the methyl groups of WY
14,643 and the side chain atoms of Phe122. Due to the two flips, the overall the RMS deviation is large (1.7 Å) for
the 21 pairs of inhibitor atoms corresponding to the protein free and hAR bound complex.
Binding of WY 14,643 does not perturb the core of the hAR active site especially near anion binding vicinity,
but causes small structural changes in a loop proximal to the active site location. Several hydrophobic and other
residues Trp20, Val47, Tyr48, His110, Trp111, Phe121, Phe122, Pro218, Trp219, Cys298 of hAR and nicotinamide
ring of NADP+ 318 encompass the WY 14,643 binding site. Upon WY 14,643 binding to the holoenzyme, much
of molA remains unperturbed, as evidenced by an RMS deviation of 0.12 Å over 312 pairs of Cαatoms; residues
Trp20, Val47, Tyr48, His110, Trp111, Pro218, Trp219, Cys298 and nicotinamide ring of NADP+ 318 show no
substantial conformational change. However residues Phe121 and Phe122 show the most noticeable structural
movement, about 0.5 Å (Fig. 4b). Interestingly, residue Phe122 undergoes a conformational change with the corresponding RMS deviation of 0.67 Å over its 11 atoms. This change causes the adjacent residue Phe121 to move its
side chain as well. The conformational changes that residues Phe122 and Phe121 undergo make their side chains
parallel to the 2,3-xylidino moiety of WY 14,643 in the ternary complex.
The RMS deviation is 0.09 Å between the 48 atoms of molA NADP+ and corresponding atoms in the WY
14,643 ternary complex. Movements of the atoms in NADP+ triggered by WY 14,643 binding are minor.
Although most of the bound water molecules in the binary structure are present without significant changes in
the ternary complex, we note additional water molecules form a network of hydrogen bonds between WY 14,643
and hAR in the ternary complex. Among the water molecules, some that occupy specific sites in the hAR binary
complex, are still present in the WY 14,643 ternary complex almost around the same locations, but a few have
shifted slightly. However, in the WY 14,643 ternary complex a distinct cluster of water molecules, W352, W392,
W484, and W528 are situated around the polar atoms of the inhibitor of molA to form bridging interactions with
hAR atoms (Fig. 5b). The corresponding water molecules in molB are W390, W386, W396, and W553, respectively.

Comparison of hAR•NADP+•WY 14,643 complex with other ternary complexes. There are several hAR inhibitor complex structures available but WY 14,643 is chemically divergent from all these inhibitors.
Structures of PDB entries 4prr and 4qr6 of hAR ternary complexes with inhibitors 3-[3-(5-nitrofuran-2-yl)phenyl]propanoic acid and 2-[2-(1,3-benzothiazol-2-ylmethylcarbamoyl)-5-fluoro-phenoxy]acetic acid were compared with the WY 14,643 complex structure because these inhibitors partially share in common the presence
of a carboxylate moiety with a connector atom (CH2, O, S) linking it to an aromatic ring by the same number of
Scientific Reports | 6:34394 | DOI: 10.1038/srep34394
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NADP+
Atoms

dimeric hAR (ternary) complex

dimeric hAR (binary) complex

atom

residue

distance (Å)

atom

residue

OG

Ser263

2.7

OG

Ser263

2.67

OG1

Thr265

2.7

OG1

Thr265

2.64

NZ

Lys262

2.7

NZ

Lys262

2.63

N

Val264

3.1

H

W135

2.6

H

W132

2.79

H

W203

2.6

H

W49

2.54

AO2*

H

W135

3.0

H

W132

2.9

AO2*

NH1

Arg268

3.3

NH1

Arg268

3.18

AO3*

NE2

BGln26

3.0

OE1

BGln26

3.16

AO3*

H

W135

2.8

OD2

Asp216

3.12

AN7

ND2

Asn272

3.07

AN1

H

W35

2.55

AN6

OD1

Asn272

2.93

OE2

Glu272

2.81
3.12

AOP1
AOP2
AOP3

AO1
AO2

distance (Å)

N

Ser214

3.1

N

Ser214

N

Leu212

2.8

N

Leu212

2.86

N

Lys262

2.9

N

Lys262

2.97

NO1

NZ

Lys21

2.9

NZ

Lys21

2.83

NO2

OG

Ser210

2.9

OG

Ser210

2.76

OG

Ser214

2.7

NO5*

N

Ser210

3.2

N

Ser210

3.07

NO2*

OD2

Asp43

2.7

OD2

Asp43

2.58

NO3*

N

Trp20

2.9

N

Trp20

2.88

NO3*

N

Trp19

3.2

N

Thr19

3.11

NN7

OE1

Gln183

3.0

OE1

Gln183

3.09

OG

Ser159

2.8

OG

Ser159

2.80

ND2

Asn160

2.8

ND2

Asn160

2.79

NO7

Table 3. Distances between cofactor polar atoms and that of hAR or solvent. A-first molecule (molA);
B-second molecule (molB) of the dimer; W-water molecule.

WY 14,643
Atom

dimeric hAR (ternary)

B1468•PPARα molB (4BCR)

A1469•PPARα molA (4BCR)

atom

residue

distance (Å)

atom

residue

distance (Å)

atom

residue

distance (Å)

OH

Tyr48

2.9

OH

Tyr314

2.9

ND1

His274

2.6

NE

His110

2.7

NE2

His440

3.5

OH

Tyr464

3.0

NE

His110

3.2

OH

Tyr314

3.1

NE1

Trp111

3.1

OG

Ser280

2.4

SH

Cys298

3.9

H

W381

3.3

N3

NE1

Trp20

3.2

N2

H

W381

2.7

OG

Ser280

3.5

OG

Ser280

3.3

O1

O2
S

N1

Table 4. Atomic distances between polar atoms of WY 14,643 and that in hAR ternary complex and PPAR
complex. W-water molecule; WY 14,643 atoms are labeled differently in hAR and PPARαstructure coordinate
set 4BCR. Atom labels matched in protein complexes hAR/4BCR-B1468/B4BCR-B1470 are C1/CAA/CAA,
C2/CAP/CAP, C3/CAG/CAG, C4/CAF/CAF, C5/CAH/CAH, C6/CAT/CAT, C13/CAR/CAR, C14/CAB/CAB,
N1, NAM/NAM, C7/C4/C4, N2/N3/N3, C8/C2/C2, N3/N1/N1, C9/C6/C6, C10/C5/C5, Cl/Cl6/Cl6, S/SAN/SAN,
C11/CAJ/CAJ, C12/CAO, O1/OAD/OAD, O2/OAC/OAC.

bonds. These complex structures superimpose RMSDs of 0.26 Å and 0.23 Å over 247 and 251 CA atoms of the
WY 14,643 complex structure. However residues Phe115, Phe121-Val130, Ala299-Ser302 have shifted in WY
14,643 compared to these complexes. The carboxyl moiety of all these three inhibitors make very similar interactions with same residues of hAR but the phenoxy ring of 4qr6 overlaps with pyridine of WY 14,643 more than
the phenyl group of 4prr (Fig. 6). Nevertheless furan and benzothiazol groups of 4prr and 4qr6 collide into the
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Figure 3. (a) Omit map corresponding to WY 14,643 in the hAR ternary complex. Simulated annealing
refinement was performed on a copy of the coordinates omitting the inhibitor. The resulting Fo-Fc omit map
is contoured at ±3.5 sigma (blue density is positive, red density is negative). In the refined structure, WY
14,643 is bound to hAR through a network of interactions O1•••OH of Tyr48, O1•••NE of His110, O2•••
NE of His110, O2•••NE1 of Trp111, S•••SH of Cys298, S•••H of H2O381, N3•••NE1 of Trp20, N2•••H of
H2O381. (b) Low temperature crystal structure of protein free WY 14,643 with thermal ellipsoid representation.
Nomenclature adopted by the PDB V3 is shown in orange.

Leu300 as found in the WY 14,643 structure. The shift seen in the loop 299–302 between these complexes may be
to accommodate different inhibitors in the 4prr and 4qr6 parallel to Tyr111 and perpendicular to Phe122 whereas
in WY 14,643 perpendicular to Tyr111 and parallel to Phe122. This is because the bend around the CH2/O/S is
different and phenyl/fluorophenoxy/pyrimidinyl groups and the rest of the inhibitors occupy different sites of the
cavity/pocket than WY 14,643 in the hAR complexes.

Discussion

Fluorescence spectroscopy is one of the most sensitive methods for studying structural changes in molecules.
It can provide important information about (1) the overall conformation, (2) the presence of ligands, cofactors, substrates or inhibitors and (3) the interactions with and about intramolecular distances between specific
chromophoric groups. For this reason the knowledge of the fluorescence properties is important in studies of
structure-binding-function relationships. Quenching reactions are particularly key in this respect25 to follow
binding events. Quenching of protein fluorescence by external quenchers is a useful technique for understanding
the extent of exposure of the aromatic, side chains and to characterize their microenvironment26 especially to
evaluate non-polar/vdW type interactions. As a result a variety of fluorescence quenching methodologies have
been established27,28 to study ligand binding to biological molecules.
Current fluorescence quenching data imply oxidized cofactor NADP+ binds hAR with 2-fold higher affinity than the reduced cofactor NADPH. The difference between the oxidized and reduced forms of the cofactor
resides in the nicotinamide ring which is aromatic and nonaromatic, respectively. The difference in planarity/
electronics between the nicotinamide rings of the oxidized and reduced cofactors may be the major cause for the
2-fold difference reflected in the current measurements. The microenvironment surrounding the nicotinamide
ring binding pocket might fit the ring in two unalike oxidation states differently. Hence the alterations in their
interactions are reflected in the fluorescence signals.
Depending on the inhibitor used, inhibition patterns against aldehyde substrate for inhibition of AR are
observed to be either uncompetitive or non-competitive. These observed inhibition patterns may imply the following scenarios that not all ARI bind at the enzyme active site, that the conformational change associated with
nucleotide exchange is responsible for the rate determining step, that ARIs bind to both *E•NADP+ and *E•
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Figure 4. (a) Superposition of hAR binary hAR•NADP+ (PDB ID 3Q65) and ternary hAR•NADP+•WY
14,643 complexes. The Cαtrace is shown for all atoms. Cartoon strands illustrate the orientation of the barrel.
The binary complex is shown in light colors; the ternary complex is shown in dark colors. Overall, the structural
differences between the binary and ternary complexes are very small. The red dots highlight the loop region
120–137 in which F122 (labeled) contacts the WY 14,643 (orange) 2,3-xylidino moiety and moves up to 0.5 Å.
(b) Zoomed view around the active site of binary and ternary complex of hAR molA with NADP+ and WY
14,643. Residues are colored as in panel (a).

NADPH, that competition between substrate and inhibitor is masked in the overall rate of the reaction, or that
tight binding causes non-competitive inhibition pattern.
Though the differences in pH, concentrations and different types of buffers may contribute to the disparity
seen in the values/patterns of the parameters under consideration, employing fixed but different NADPH concentrations (0.15 mM compared to 60 μM) with different protein concentrations (0.5 mM versus 0.5 μM) will make
significant variations observed by the above two methods. Furthermore 3-APADP+ used in the kinetic studies is
chemically diverse with different affinity than NADP+ which is used in the quenching studies as 3-APADP+ is not
currently commercially readily available. Therefore as Dr. Grimshaw demonstrated29 hAR•NADP+•WY 14,643
complex is anticipated to show significant inhibition of the steady-state turnover rate. The binding location of WY
14,643 in the active site as revealed by this ternary hAR complex structure reinforces such functional phenomenon.
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Identification code

CCDC 1476501

Empirical formula

C14H14ClN3O2S

Formula weight
Temperature

323.79
100(2) K

Wavelength

0.71073 Å

Crystal system

Monoclinic

Space group
Unit cell dimensions
Volume
Z

P 21/c
a =  7.1294(3) Å

α  =  90°

b =  22.6174(9) Å

β  =  105.003(2)°

c =  9.2174(4) Å

γ  =  90°

1435.63(10) Å3
4

Density (calculated)

1.498 Mg/m3

Absorption coefficient

0.419 mm−1

F (000)
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta =  25.242°
Absorption correction
Max. and min. transmission
Refinement method
Data/restraints/parameters
Goodness-of-fit on F2

672
0.21 ×  0.21 × 0.21 mm3
1.801 to 30.555°
−9 ≤ h ≤ 10, −32 ≤ k ≤ 31, −13 ≤l ≤ 12
36,288
4,396 [R (int) =  0.0452]
100.0%
Semi-empirical from equivalents
0.8622 and 0.7643
Full-matrix least-squares on F2
4,396/0/200
1.042

Final R indices [I > 2sigma (I)]

R1 =  0.0321, wR2 =  0.0740

R indices (all data)

R1 =  0.0427, wR2 =  0.0797

Largest diff. peak and hole

0.451 and −0.296 e.Å−3

Table 5. Crystal data and structure refinement for protein free WY 14,643.

Figure 5. (a) Superposition of free and hAR-bound conformations of the WY 14,643 molecule. The two
conformations are superimposed using only the atoms in their the pyrimidine rings. Arrows show the two
torsion angles that rotate ~180° upon binding hAR in the ternary complex. (b) Waters (cyan spheres) stabilized
by the presence of the WY 14,643 ligand in molA of hAR•NADP+•WY 14,643. The waters shown here are
particular to the ternary complex and not observed in the hAR•NADP+ binary complex (PDB ID 3Q65). The
corresponding water molecules in molB are W390, W386, W396, and W553, respectively.

The non-selective kinase inhibitor, staurosporine is an ATP non-competitive inhibitor of protein kinase C30
but the crystal structure of its complex with another form of protein kinase C31 as well as with protein kinase
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Figure 6. Comparison of binding geometries of WY 14,643 and two related ligands in the active site
of hAR. Panel (a) shows WY 14,643 forms three hydrogen bonds between its carboxylate moeity and hAR
(dashed red lines). These bonds are conserved among all thre analogs. Panel (b) shows 2-[2-(1,3-benzothiazol2-ylmethylcarbamoyl)-5-fluoro-phenoxy]acetate bound to hAR (PDB code 4qr6). Note Leu300 moves to
accommodate binding of its 1,3-benzothiazol ring. Panel (c) shows a similar movement in the hAR complex
(PDB code 4prr) with 3-[3-(5-nitrofuran-2-yl)phenyl] propanoate.

A32,33 indicates binding in the ATP-binding pocket. Also the tyrphostin inhibitor PP1, is an ATP non-competitive
inhibitor of pp60c−src 34 however it is shown to bind to the ATP-binding pocket of another kinase, Hck35. Similarly
the structure reveals binding of WY 14,643 in the active site of the hAR ternary complex.
Fluorescence data show WY 14,643 binds hAR•NADP+ as well as hAR•NADPH binary complexes with
almost equal affinity. The x-ray crystal structure reported here confirms the binding of WY 14,643 to the hAR•
NADP+ binary complex. In addition the structure of the hAR•NADP+•inhibitor ternary complex reveals small
conformational changes associated with residues Phe122 and Phe121 upon WY 14,643 binding to hAR•NADP+
the binary complex. The carboxylate moiety of WY 14,643 interacts with polar atoms of His, Tyr, Trp and NAPD+
that have aromatic character and is surrounded by other side chains that are aromatic too. However these residues do not demonstrate significant conformational or positional changes upon binding of the inhibitor’s carboxyl moiety; large conformational changes would likely interfere with the long range Πinteractions across this
pocket. Therefore the majority of the differences reported by the fluorescence titration may originate from the
Scientific Reports | 6:34394 | DOI: 10.1038/srep34394
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Figure 7. Superposition of free and PPAR bound conformations of WY 14,643. Conformations of WY
14,643, B1468 (white) B1470 (brown) bound to PPARαare superimposed using only the atoms in their the
pyrimidine rings of protein free WY 14,643 (purple).
microenvironment. Overall the current observations reinforce interpretations from previous kinetic data that
WY 14,643 targets the hAR active site selectively in the presence of oxidized as well as reduced cofactors, NADP+
and NADPH.
WY 14,643 with its strong hypolipidemic effects is known to be an agonist of PPARαand an inhibitor of
hAR; structural evidence suggests that these two biological roles are facilitated by different conformations of this
molecule. As reported (PDB entry 4BCR)36 WY 14,643 binds to two types of sites on PPARα–an active site and a
secondary site. Since PPARαwas observed in homodimeric form, there are two examples of each site: molecules
labeled A1468 and B1468 bind to the agonist pocket and are fully buried by the protein, and molecules labeled
A1469 and B1470 bind to secondary sites which are partially exposed to solvent. The conformation of WY 14,643
differs between agonist and secondary sites, varying by the same torsion angles that were found to differ between
free and hAR-bound inhibitor molecules (Fig. 7) and by similar magnitudes. The variation can be explained by
the large difference between the structure of the agonist and secondary sites. In the agonist pocket, WY 14,643
is bound through all three of its functional moieties with numerous polar and nonpolar contacts, whereas in the
secondary site, the carboxylate moiety is mostly solvent exposed with only a single polar contact less than 3.4 Å
(Table 4). Moreover, these two PPARα-bound conformations of WY 14,643 differ from the hAR-bound and free
inhibitor conformations. The PPARαagonist pocket and secondary site conformations (21 atoms) superimpose
with RMSD of 1.5 Å and 1.3 Å with the hAR•NADP+•WY 14,643 complex and 1.7 Å and 1.8 Å with free WY
14,643, respectively.
Administration of WY 14643 has been shown to protect against cardiomyocyte apoptosis following ischemia/
reperfusion or biomechanical stress in the mouse heart37. In patients with type 2 diabetes, myocardial energetic
status index (phosphocreatine-to-ATP ratio) negatively correlates with plasma free fatty acid (FFA) concentrations38. Diabetic patients have abnormal cardiac energy metabolism associated with high FFA concentrations.
Direct energy-dissipating methods such as reduction of fat accumulation in adipocytes, or alteration of fatty acid
metabolism, could be used to improve insulin resistance in type 2 diabetic patients39. In type 2 diabetes and even
in individuals with family history of diabetes, mitochondrial metabolism, ATP synthesis are reduced in concert
with a reduction of key factors regulating mitochondrial biogenesis, including amino acid biosynthesis and fatty
acid oxidation40–42. Findings reported in the current study along with the information in the literature imply
hAR is a target for WY 14,643 mechanism of action. Therefore the hAR mediated actions may contribute to the
physiological outcomes of the clinical application of WY 14,643. Besides results from current binding and structure determination demonstrate that only one molecule of WY 14,643 binds to hAR and its carboxylate moiety
occupies in the anion binding pocket under experimental conditions explored.

Methods

Production of recombinant hAR.

His-tagged recombinant hAR was expressed in E. coli BL21 cells that
were grown in Luria-Bertani broth containing 50 mg/L ampicillin with constant shaking in rotary shaker to reach
the OD600 = 0.6–0.8 at 37 °C and 240 rpm. The protein expression was induced by supplementing 1 mM isopropyl-1-thio-galactopyranoside (IPTG) in the culture medium. The cells were harvested after 3–4 hrs by centrifugation (6000 g, 10 min) and resuspended in 50 mM sodium phosphate buffer (pH 7.0) containing 300 mM NaCl
and 1 mM 2-mercaptoethanol and lysed by ultra-sonication. The hAR was isolated from the lysate separated by
centrifugation at 10,000 g for 1.0 hr at 4 °C. The supernatant containing hexa-His-hAR was incubated for 1–2 hr
by constant gentle mixing with Talon metal affinity matrix (Clontech, Mountain View, USA), later matrix slurry
was passed through column and washed with 50 mM sodium phosphate buffer (pH 7.0) having 300 mM NaCl and
1.0 mM 2-mercaptoethanol. The protein was eluted with 150 mM imidazole in 50 mM sodium phosphate buffer
(pH 7.0) containing 300 mM NaCl and 1 mM 2-mercaptoethanol and dialyzed in the 50 mM sodium phosphate
buffer (pH 7.0) containing 1 mM 2-mercaptoethanol. The His-tag was removed by thrombin cleavage (Novagen,
USA) as per manufacturer’s instructions. hAR was further purified by anion exchange on DEAE Sephadex A25
column by binding with DEAE Sephadex A 25 matrix. The concentration of hAR was determined by the Bradford
assay (Bio-Rad, Hercules, USA), the purity was assessed by SDS-PAGE and the enzyme activity was determined
by using 10 mM DL-glyceraldehyde and 0.15 mM NADPH as substrate and cofactor respectively.

Fluorescence titration for the binding of cofactors and inhibitors to hAR.

Fluorescence titration was performed for the binding of NADPH to hAR at a protein concentration of 0.5 μM in 5 mM sodium
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phosphate buffer (pH 7.0) containing 100 μM DTT. The titration for NADP+ binding to hAR was conducted at
a protein concentration of 0.5 μM in 10 mM Tris-HCl buffer (pH 9.0) containing 100 μM DTT in 1.4 ml quartz
cuvette by measuring fluorescence by SpectraMax M2 (Molecular Device, CA). The concentration of protein•
NADP+/NADPH complexes formed were measured by extensive quenching of protein fluorescence by varying the concentrations of NADP+/NADPH at excitation and emission wavelengths of 295 and 365 nm, respectively following the procedure described by43,44. This method was extended for inhibitor (WY 14,643) binding
to enzyme•NADPH complex at protein concentration of 0.5 μM in 5 mM sodium phosphate buffer (pH 7.0)
containing 100 μM DTT by keeping saturated fixed 60 μM concentration of NADPH and by varying the concentrations of WY 14,643. The binding of inhibitor (WY 14,643) to enzyme•NADP+ complex was measured at 0.5 μ
M protein concentration in 10 mM Tris-HCl buffer (pH 9.0) containing 100 μM DTT by keeping saturated fixed
60 μM concentration of NADP+ and varying the WY 14,643. The concentrations of enzyme•NADP+/NADPH•
inhibitor complex formed were measured by quenching of fluorescence protein•NADP+/NADPH complexes
with excitation and emission wavelengths 295 and 365 nm, respectively.

Determination of binding dissociation constants and stoichiometric coefficients of cofactors
and WY 14,643 to hAR using fluorescence titration data. The methodology described by van de

Weert 2010 was followed in the binding constant determination27,28. The fractional saturation (α) of protein by
cofactors (NADP+/NADPH) and by inhibitor (WY 14,643) binding to protein can be expressed in the form of
fluorescence as follows;
α=

(F 0 − F )
(F 0 − F ∞)

(1)

where F0 is the fluorescence in absence of quenchers (cofactors and inhibitor) denoted by L. F is the fluorescence
at a given quencher concentration and F∞ is the fluorescence from a protein “saturated” of quencher. Assuming
that quenchers bind to protein with molar stoichiometry of 1:n as shown in the equation (2);
P + nL ⇔ P · nL

(2)

where n represents the order (stoichiometry) of kinetic reaction, k+1 and k−1 represent binding and dissociation
rate constants respectively. The equilibrium dissociation constant can be expressed as below;
Rate Of Binding = k+1 ⋅ (1 − α) ⋅ n ⋅ P 0 [L]n

(3)

Rate Of Dissociation = k−1 ⋅ α ⋅ n ⋅ P 0

(4)

Rate Of Binding = Rate Of Dissociation

(5)

k+1 ⋅ (1 − α) ⋅ n ⋅ P 0 [L]n = k−1 ⋅ α ⋅ n ⋅ P 0

(6)

At equilibrium;

The equilibrium dissociation constant can be expressed as below;
Kd =

k−1
(1 − α) ⋅ [L]n
=
k+1
α

(7)

[L]n
K d + [L]n

(8)

This equation can be re-arranged to,
α=

when quencher concentration (L) ≈Initial concentration (L ) then equation (8) can be expressed as follows;
0

α=

[L0]n
K d + [L0]n

(9)

The binding dissociation constants and stoichiometry for the binding of quenchers (cofactors and inhibitor)
to protein were calculated by non-linear fitting to the experimental fluorescence data and results are shown in
Table 1.

X-ray crystal structure determination of protein free WY 14,643. Crystals suitable for structure
determination were obtained by crystallization of 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid
(also called WY 14,643 or Pirinixic acid) from its solution in aqueous ethanol at room temperature. A single crystal with dimensions 0.21 ×  0.21 × 0.21 mm3 was mounted on a glass fiber in a random orientation. Initial examination and data collection were performed using a Bruker APEX II Charge Coupled Device (CCD) Detector
single crystal x-ray diffractometer using graphite monochromated Mo Kαradiation (λ  = 0.71073 Å). Preliminary
unit cell constants were determined with a set of 36 narrow frames. Intensity data were collected using ϖ and φ
scans at a crystal to detector distance of 4.00 cm. The collected frames were integrated using an orientation matrix
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determined from the narrow frame scans. Bruker Apex2 and SAINT software packages45 were used for data collection and integration. Final unit cell constants were determined by global refinement of xyz centroids of threshold reflections from the complete data set. Collected data were corrected for systematic errors using SADABS46
based on the Laue symmetry using equivalent reflections. Crystal data and intensity data collection parameters
for WY 14,643 obtained at low temperature are listed in Table 5.
Structure solution and refinement were carried out using the SHELXTL- PLUS software package47. The structure was determined by direct methods and refined successfully in the monoclinic space group, P 21/c. Full matrix
least-squares refinement was carried out by minimizing Σw(Fo2 −  Fc2)2. The non-hydrogen atoms were refined
anisotropically to convergence with final residual values: R1 = 3.2% and wR(F2) = 8.0%. All OH and NH hydrogen atoms were located from difference Fourier maps and were refined freely using isotropic thermal parameters
like in the structure determination of fenofibric acid and fenofibrate following established procedure47–49. All
other H atoms were treated using appropriate riding models (AFIX m3). Refinement parameters for the final
structure of WY 14,643 are listed in Table 5. See supplementary information.

Crystal structure determination of hAR with WY 14,643. Crystals of hAR•NADP+•WY 14,643 were

generated using the hanging drop vapor diffusion method following a procedure that we previously established
for the holoenzyme50. Protein, NADP+ and WY 14,643 solutions were mixed to achieve a molar ratio of 1:3:1.2
for the protein to cofactor to inhibitor. Crystals were briefly transferred to a solution containing the reservoir
solution supplemented with 35% glycerol and flash-cooled by plunging them into liquid nitrogen. Data were
collected at 100 K using beamline 9-2 at the Stanford Synchrotron Radiation Laboratory (SSRL) with an exposure
time of 90 sec per 0.5° frame, a 250 mm crystal-to-detector distance, and wavelength of 0.9795 Å. The beamline
was equipped with an ADSC Quantum 315 CCD detector. The data were processed and scaled to 1.8 Å resolution with XDS51, AIMLESS52,53 and AUTOPROC54 yielding an Rmerge of 12.2%. The crystal belonged to space
group P212121 and contained two hAR•NADP+•WY 14,643 complexes in the asymmetric unit. Initial phases
were obtained by the difference Fourier method, using the holoenzyme (PDB ID 3Q65) (excluding solvent molecules) as the starting model. Initial rigid-body refinement and subsequent individual atomic refinement were
performed using the programs REFMAC53,55 and BUSTER56. Model building was performed with the program
COOT57. Clear electron density allowed the positioning of the WY 14,643 ligand and solvent molecules. The final
model was validated with the following structure validation tools: PROCHECK58, ERRAT59 and VERIFY3D60.
The Ramachandran plot indicates 91% of the residues lie in the most favoured regions and 9% of the residues lie
in the additionally favoured regions. The ERRAT score was 96.7%. Details of the data collections and the refinement statistics are shown in Table 2.
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